Gromadzka G, Czerwiska J, Krzemiska E, et al (2024) Wilson's disease-crossroads of genetics, inflammation and immunity/autoimmunity: clinical and molecular issues
Jeffrey I
We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content
You may want to check to see if your insurance covers the medicine on your plan since the cost can be expensive

Dissolving 0.33g of Fmoc-His-Aib-OSu crude product and 1g of Boc protected Arg34GLP-1 (9-37) in 20mL of N, N-dimethylformamide, adding 2mL of N, N-diisopropylethylamine, reacting at room temperature for 8h, adding 20mL of mixed solution of methyl tert-ether and petroleum ether, precipitating and centrifuging to obtain Fmoc-GLP-1 (Lys-Lys) 20 Boc), the crude product was added to a trifluoroacetic acid solution, stirred at low temperature for 2 hours, 400mL of methyl-tert-ether was added, centrifugation was performed to obtain 0.98g of a solid, the crude product was dissolved in 20mL of N, N-dimethylformamide and 2mL of N, N-diisopropylethylamine was added, 0.33g of the side chain of compound 1 was dissolved in 2mL of N, N-dimethylformamide, slowly added dropwise to the reaction solution, reacted at room temperature for 2 to 3 hours, added to 400mL of a mixed solution of methyl-tert-ether and petroleum ether, centrifuged to obtain a solid, the above solid was added to 4mL of a 20% piperidine DMF solution, reacted at room temperature for 1 hour, and 40mL of a mixed solution of methyl-tert-ether and petroleum ether was added, centrifuged to obtain a solid, the above solid was added to 10mL of a cleavage solution (TFA: TIS: DCM =95 2), reacted at room temperature for 2 to 4 hours, 100mL of a mixed solution of methyl-tert-ether and petroleum ether was added, centrifugation to obtain 0.8g of a solid having a purity of57.15%, the specific liquid phase map is shown in FIG

Sowa says: "I've had patients discover their employer's diabetes prevention program covered their medication because they had pre-diabetes